StageZero Life Sciences to Present at the New York City based Investor Summit on March 25th-26th.

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Return to homepage

NEW YORK, NY / ACCESSWIRE / March 18, 2020 / StageZero Life Sciences (TSX:SZLS), is spearheading multiple cancer detection screening through their next generation test, Aristotle. StageZero Life Sciences will be presenting at this year's New York City based Investor Summit on March 25th-26th.

During the current climate of concern, The Spring Investor Summit will now take place virtually, featuring over 500 registered executives and investors.

Investors will still be able to view all the company presentations directly in the conference event platform on the event days. 1:1's will now be scheduled and conducted via phone lines with a dedicated PIN for each meeting.

You can view our company presentation via webcast here: https://www.webcaster4.com/Webcast/Page/2038/33701 on March 26th, 2020 at 09:40 a.m. EST.

About StageZero Life Sciences

StageZero Life Sciences is dedicated to the early detection of cancer and multiple disease states through whole blood. Aristotle®, our next generation test, is a panel for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle is built on our proven and proprietary Sentinel Principle Technology Platform which has been validated on 10,000 patients and used to develop the first liquid biopsy for Colorectal Cancer, with further validation currently underway. In addition to building a pipeline of products for early cancer detection, the Company operates a CAP accredited and CLIA certified reference laboratory based in Richmond, Virginia that offers the ColonSentry® test as well as licensed biomarker tests for lung, breast and prostate cancers. To learn more visit www.stagezerolifesciences.com.

The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors.

To register as a presenting company: please contact Cassandra Miller ([email protected])

To request complimentary investor registration: please visit our website at www.microcapconf.com

News Compliments of ACCESSWIRE

FOR MORE INFORMATION

Please visit: www.microcapconf.com

Or, contact Cassandra Miller at [email protected]

SOURCE: Stage Zero Life Sciences



View source version on accesswire.com:
https://www.accesswire.com/581278/StageZero-Life-Sciences-to-Present-at-the-New-York-City-based-Investor-Summit-on-March-25th-26th

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).
LinkedIn
StockTwits
Twitter